Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy
Nilanjan Adhikari, Tarun Jha, Balaram Ghosh
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 8827-8869
Closed Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 83
Carboranes as unique pharmacophores in antitumor medicinal chemistry
Yu Chen, Fukuan Du, Liyao Tang, et al.
Molecular Therapy — Oncolytics (2022) Vol. 24, pp. 400-416
Open Access | Times Cited: 71
Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors
Goverdhan Lanka, Darakhshan Begum, Suvankar Banerjee, et al.
Computers in Biology and Medicine (2023) Vol. 166, pp. 107481-107481
Closed Access | Times Cited: 58
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 24
Macrocycles and macrocyclization in anticancer drug discovery: Important pieces of the puzzle
Chao Zhang, Fenfen Liu, You‐Ming Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116234-116234
Closed Access | Times Cited: 18
Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer
Sravani Pulya, Ambati Himaja, Milan Paul, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12033-12058
Closed Access | Times Cited: 29
The role of HDAC3 and its inhibitors in regulation of oxidative stress and chronic diseases
Ruyuan He, Bohao Liu, Boxin Geng, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 26
Hepatic HDAC3 Regulates Systemic Iron Homeostasis and Ferroptosis via the Hippo Signaling Pathway
Hongen Meng, Yingying Yu, Enjun Xie, et al.
Research (2023) Vol. 6
Open Access | Times Cited: 23
Quantitative structural assessments of potential meprin β inhibitors by non-linear QSAR approaches and validation by binding mode of interaction analysis
Suvankar Banerjee, Sandip Kumar Baidya, Balaram Ghosh, et al.
New Journal of Chemistry (2023) Vol. 47, Iss. 15, pp. 7051-7069
Closed Access | Times Cited: 22
Arresting the bad seed: HDAC3 regulates proliferation of different microglia after ischemic stroke
Yue Zhang, Jiaying Li, Yongfang Zhao, et al.
Science Advances (2024) Vol. 10, Iss. 10
Open Access | Times Cited: 13
Epigenetic modifications in obesity‐associated diseases
Yiqian Long, Chao Mao, Shuang Liu, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 8
The role of protein acetylation in carcinogenesis and targeted drug discovery
Jingru Yang, Cong Song, Xianquan Zhan
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 28
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Sk. Abdul Amin, Samima Khatun, Shovanlal Gayen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115594-115594
Closed Access | Times Cited: 19
Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy
Fabian B. Kraft, Maria Hanl, Felix Feller, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 356-356
Open Access | Times Cited: 16
Targeting histone deacetylases in head and neck squamous cell carcinoma: molecular mechanisms and therapeutic targets
Mengchen Xu, Yiming Hou, Na Li, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer
Sravani Pulya, Tarun Patel, Milan Paul, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114470-114470
Closed Access | Times Cited: 27
Histone Deacetylase 3: A Potential Therapeutic Target for Atherosclerosis
Liping Jiang, Xiao-Hua Yu, Jin-Zhi Chen, et al.
Aging and Disease (2022) Vol. 13, Iss. 3, pp. 773-773
Open Access | Times Cited: 24
Hydrazide-Based Class I Selective HDAC Inhibitors Completely Reverse Chemoresistance Synergistically in Platinum-Resistant Solid Cancer Cells
Fabian B. Kraft, Lukas Biermann, Linda Schäker‐Hübner, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 19, pp. 17796-17819
Closed Access | Times Cited: 5
HDAC3 inhibitors: a patent review of their broad-spectrum applications as therapeutic agents
Thabo Brighton Makgoba, Erika Kapp, Samuel Egieyeh, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 4, pp. 273-295
Open Access | Times Cited: 4
Exploration of Hydrazide-Based HDAC8 PROTACs for the Treatment of Hematological Malignancies and Solid Tumors
Chunlong Zhao, Jianqiu Zhang, Hangyu Zhou, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 14016-14039
Open Access | Times Cited: 4
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)
Suvankar Banerjee, Balaram Ghosh, Tarun Jha, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 10, pp. 1019-1045
Closed Access | Times Cited: 4
Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
Ekta Shirbhate, Vaibhav Singh, Rakesh Kore, et al.
Expert Review of Anticancer Therapy (2025)
Closed Access
HDAC3 as an Emerging Therapeutic Target for Alzheimer's Disease and other Neurological Disorders
Yonghe Li, Taha Izhar, Takahisa Kanekiyo
Molecular Neurobiology (2025)
Closed Access
Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy
Zhijie Wang, Haiqi He, Xiaotong Liao, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Design and synthesis of pyridine-based benzamides as potent HDAC3 inhibitors as an armament against breast cancer with in vivo validation
Ambati Himaja, Ganesh Routholla, Tarun Patel, et al.
European Journal of Medicinal Chemistry (2025) Vol. 291, pp. 117636-117636
Closed Access
Page 1 - Next Page

Scroll to top